Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion

Rheumatology

Volumn 50, Issue 1, 2011, Pages 243-244

  Walker, Ulrich A ^a   Courvoisier, Delphine S ^b   Dudler, Jean ^c   Aeberli, Daniel ^d   von Kempis, Johannes ^e   Scherer, Almut ^f   Finckh, Axel ^g  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e Division of Rheumatology and Rehabilitation   (Switzerland)

^f Swiss Clinical Quality Management Foundation   (Switzerland)

^g GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBIOTIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; LEFLUNOMIDE; METHOTREXATE; PLACEBO; PREDNISONE; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIBIOTIC THERAPY; B LYMPHOCYTE; BURSITIS; DISEASE CONTROL; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYSIPELAS; HEALTH CARE NEED; HERPES ZOSTER; HUMAN; LETTER; PNEUMONIA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; URINARY TRACT INFECTION;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; SWITZERLAND;

EID: 79951701442     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keq258     Document Type: Letter

References (6)

1. Finckh A, Ciurea A, Brulhart L et al. Which subgroup of rheumatoid arthritis patients benefits from switching to rituximab versus alternative anti-TNF agents after previous failure to anti-TNF agent? Ann Rheum Dis 2009; 69:387-93.
2. Uitz E, Fransen J, Langenegger T, Stucki G. Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in Rheumatoid Arthritis. Rheumatology 2000;39:542-9.
3. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.
4. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009;68:25-32.
5. Weinblatt ME, Schiff MH, Goldman A et al. Selective co-stimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomized clinical trial. Ann Rheum Dis 2006;66: 228-34.
6. Genovese MC, Breedveld FC, Emery P et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009;68: 1894-7.